Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources

Alembic Pharmaceuticals Australia Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

Cancellation by sponsor (320)
ARTG (171)
Prescription medicine registration (8)

Date

2024 (12)
2023 (257)
2022 (10)
2021 (84)
2020 (22)
2019 (2)
2018 (27)
2017 (48)
2016 (3)
2015 (11)
2013 (17)
2012 (6)

Results for "[search-keyword]"

Search

Sponsor content

499 result(s) found, displaying 141 to 150

OSELTAMIVIR APL oseltamivir (as phosphate) 75 mg hard capsule blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESTIXINE desvenlafaxine 100 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESLEM desvenlafaxine 50 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESVENLAFAXINE APPL desvenlafaxine 50 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESVOLIN desvenlafaxine 50 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESVOLIN desvenlafaxine 100 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESVENLAFAXINE APL desvenlafaxine 100 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESVENLAFAXINE APL desvenlafaxine 50 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESVENLAFAXINE AGH desvenlafaxine 50 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd
DESVENLAFAXINE AGHL desvenlafaxine 100 mg extended release tablet blister pack Cancelled under Section 30(1)(c) of the Act

13 February 2023

Cancellation by sponsor

Requested by Alembic Pharmaceuticals Australia Pty Ltd

Pages

First page
Previous page
…
Page 11
Page 12
Page 13
Page 14
Current page 15
Page 16
Page 17
Page 18
Page 19
…
Next page
Last page

Is there anything wrong with this page?

Help us improve the Therapeutic Goods Administration site

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook
(Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.